New Study Finds Antidepressants in Pregnancy Not the Main Culprit for Autism and ADHD — Here’s What Parents Should Know

Understanding the Concern About Antidepressants and Pregnancy

Pregnancy is a time of great joy, but it can also bring worry — especially for women who take medication for depression or anxiety. An estimated one in five pregnant women experiences mental health conditions, and many rely on antidepressants to stay well. For years, researchers have debated whether taking these medications during pregnancy might affect a child’s brain development. A new, large-scale review of the evidence offers some of the clearest answers yet, helping to settle a question that has troubled families and doctors alike.

The latest analysis, published in Lancet Psychiatry, looked at 37 studies involving nearly 25 million pregnancies. Scientists wanted to know if children exposed to antidepressants before birth were more likely to develop neurodevelopmental disorders such as autism or attention deficit-hyperactivity disorder (ADHD). What they discovered is reassuring in many ways. While a small increase in risk did show up in early calculations, that risk disappeared or became too small to be meaningful once the researchers accounted for other important factors — especially the mother’s mental health condition itself.

The Study at a Glance: What Researchers Examined

A team led by Dr. Wing Chung Chang of the University of Hong Kong conducted a systematic review and meta-analysis. This means they combined results from many high-quality studies to get a big-picture view. In total, they included data from 648,626 pregnancies in which the fetus was exposed to antidepressants and compared them with nearly 25 million pregnancies without such exposure. The average age of the mothers in the studies that reported it was 28.8 years.

The researchers looked at a range of neurodevelopmental outcomes: autism spectrum disorder, ADHD, intellectual disabilities, motor disorders, and speech and language disorders. They also examined different types of antidepressants — SSRIs (selective serotonin reuptake inhibitors), which are the most commonly prescribed class, and non-SSRI antidepressants, including tricyclic drugs like amitriptyline and nortriptyline. By comparing mothers, fathers, and even siblings, the study tried to separate the effect of medication from the effect of the mental health condition itself.

What the Numbers Actually Show

At first glance, the numbers seemed to point to a link. Prenatal antidepressant use was associated with a modestly higher overall risk of neurodevelopmental disorders in children, with a relative risk (RR) of 1.13 (95% confidence interval 1.08 to 1.18, P = 0.051). This was mainly driven by increased risks for autism (RR 1.69, 95% CI 1.24 to 2.30, P < 0.0001) and ADHD (RR 1.35, 95% CI 1.24 to 1.47, P < 0.0001).

However, those figures tell only part of the story. The critical finding was that similar associations showed up even when the mother took antidepressants before becoming pregnant, and when the father used antidepressants. This suggests that the real driver is not the medication, but rather shared family factors — such as genetics and the presence of a psychiatric condition — that influence both the likelihood of taking antidepressants and the child’s later development.

When the analysis focused on studies that compared siblings (where one child was exposed to antidepressants and another was not, within the same family), the link between prenatal antidepressant exposure and autism became non-significant. This is strong evidence that family background, not the drug, explains much of the initial association. In addition, no dose-response relationship was found: higher doses did not lead to higher risks, which is usually a red flag if a medication is truly causing harm.

Importantly, the study found no significant connection between prenatal antidepressants and intellectual disabilities, motor disorders, or speech and language disorders. The signals that existed were limited to autism and ADHD, and even those weakened dramatically after accounting for confounding factors.

The Role of Parental Mental Health, Not Just Medication

One of the biggest takeaways from this research is that a mother’s untreated depression or anxiety can itself be a risk factor for a child’s development. Many earlier studies failed to fully disentangle the effects of the medication from the effects of the underlying illness. This new analysis took great care to adjust for “confounding by indication,” which is the bias that occurs when the condition being treated (like severe depression) influences the outcome.

Dr. Chang put it plainly in an email to MedPage Today: “Our study showed a small association between prenatal antidepressant exposure and ADHD or autism spectrum disorder, which was attenuated or became non-significant after adjusting for confounding factors — in particular, confounding by treatment indication (i.e., underlying maternal psychiatric illness).” He added that the findings do not provide strong evidence that prenatal antidepressant exposure causes neurodevelopmental disorders and that antidepressant treatment should continue for pregnant women with moderate to severe depression.

Dr. Chang also emphasized a broader truth: optimizing both maternal and paternal mental health is essential for a child’s long-term neurodevelopment. This aligns with a growing understanding in medicine that family mental well-being before and during pregnancy can shape a child’s future in meaningful ways.

Expert Reactions: Seeing Past the Headlines

Dr. David Mandell of the University of Pennsylvania Perelman School of Medicine, who was not involved in the study, noted that the analysis was well-done but that many people might miss the most important part. “Most of the studies they include used administrative data to assess the association between antidepressants and neurodevelopmental disorders. In these data, it is very difficult to separate out the effects of medications from the reasons that people take those medications,” he said.

He highlighted that the study’s key strength was comparing women with depression and anxiety who did not take SSRIs with those who did. In that comparison, there was no association between medication and neurodevelopmental disorders. Dr. Mandell also pointed to the lack of a dose response as an important clue. “That further suggests that they are measuring the association between maternal psychiatric disorder and neurodevelopment, not the effects of SSRIs per se.”

An editorial that accompanied the study in Lancet Psychiatry echoed this view. Dr. Gisele Apter of the University Rouen Normandy in France and her co-authors wrote that the study’s adjustment for maternal mental health conditions is “a major factor only recently taken into account.” They added that the research “confirms some of the pre-existing knowledge on the use of antidepressants during pregnancy: that they should continue to be taken as they protect maternal mental health and do not harm fetal development. This result is of considerable impact after many contradictory and controversial studies.”

What About Specific Medications? A Closer Look at the Data

When the researchers controlled for the treatment indication closely, most individual antidepressants showed no significant link to autism or ADHD. The exceptions were the older tricyclic drugs amitriptyline and nortriptyline. Amitriptyline was associated with an increased risk of ADHD (RR 1.74, 95% CI 1.00 to 3.03), and the combination of amitriptyline and nortriptyline showed an elevated risk for autism (RR 2.02, 95% CI 1.32 to 3.10). No significant associations were found for specific SSRIs or SNRIs (serotonin-norepinephrine reuptake inhibitors) when the analysis was restricted to comparisons that minimized confounding.

The study did find that both SSRI and non-SSRI antidepressants as broad classes were associated with increased risks for autism and ADHD in the overall, unadjusted analysis. But those risks shrank dramatically after accounting for family and maternal mental health. The authors urged caution in interpreting class-level findings, as they may still be polluted by residual confounding.

The Bigger Picture: Why This Matters Now

This research arrives at a time when antidepressant use is being hotly debated in the United States. Earlier this month, Health and Human Services Secretary Robert F. Kennedy Jr. announced initiatives to reduce SSRI prescribing. Last year, a panel selected by former FDA Commissioner Dr. Marty Makary raised concerns about risks associated with SSRI use during pregnancy, though those claims were met with pushback from many medical experts. The conversation around antidepressants is often clouded by strong opinions, making high-quality evidence like this study especially valuable.

For women who are pregnant or planning to become pregnant, the stakes are personal and urgent. Untreated depression during pregnancy has been linked to premature birth, low birth weight, and long-term emotional and behavioral difficulties for the child. The risk of relapse when stopping medication is high, and the physical and emotional toll on the mother can be severe. This study reinforces that withholding effective treatment out of fear of autism or ADHD risk may not be supported by science.

What This Means for You: Practical Takeaways

If you or someone you love is navigating pregnancy while on antidepressants, here are the key points to remember:

• The link between antidepressants and autism or ADHD is very small and largely explained by other factors. When family mental health history and genetics are taken into account, the connection fades.
• Untreated mental illness carries its own risks. Severe depression and anxiety can affect a mother’s nutrition, sleep, and ability to bond with her baby, and may negatively impact the child’s development in other ways.
• Never stop prescribed medication abruptly during pregnancy without medical guidance. A sudden stop can lead to withdrawal symptoms and a return of depression or anxiety that can be harder to manage.
• Talk to your healthcare provider about the best plan for you. This conversation should weigh both the potential benefits of medication and the importance of stable mental health during pregnancy.
• Partners play a role too. The study’s finding that paternal antidepressant use showed similar associations further supports the idea that the whole family’s mental health environment matters. A supportive, healthy partner can be a protective factor.